AllianceBernstein
ABCL icon

AllianceBernstein’s AbCellera Biologics ABCL Stock Holding History

AllianceBernstein’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-39,472
Closed -$225K – 3140
2023
Q4 		$225K Buy
+39,472
New +$183K ﹤0.01% 2943
2023
Q2 		– Sell
-233,100
Closed -$1.76M – 3164
2023
Q1 		$1.76M Hold
233,100
– – ﹤0.01% 1938
2022
Q4 		$2.36M Hold
233,100
– – ﹤0.01% 1819
2022
Q3 		$2.31M Hold
233,100
– – ﹤0.01% 1798
2022
Q2 		$2.48M Buy
+233,100
New +$1.97M ﹤0.01% 1812
2022
Q1 		– Sell
-125,000
Closed -$1.79M – 3262
2021
Q4 		$1.79M Buy
+125,000
New +$1.9M ﹤0.01% 2206

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AllianceBernstein's ABCL Position: Q1 2024 in Review

AllianceBernstein sold out of AbCellera Biologics (ABCL) in Q1 2024, closing a stake of 39,472 shares — an estimated $225K sold.

AllianceBernstein first reported a position in ABCL in Q4 2021 and held it in 6 quarters. The position peaked at $2.48M in Q2 2022. 154 funds tracked by Wall St. Rank hold ABCL as of Q1 2024.

  • AllianceBernstein reported no remaining AbCellera Biologics position as of Q1 2024 after selling out during the quarter.
  • AllianceBernstein sold 39,472 AbCellera Biologics shares in Q1 2024, an estimated $225K.
  • AllianceBernstein first reported a position in AbCellera Biologics in Q4 2021 and held it in 6 quarters.
  • AllianceBernstein's AbCellera Biologics position peaked at $2.48M in Q2 2022.
  • 154 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2024.

Based on AllianceBernstein's 13F filing for Q1 2024, filed 14 May 2024.